Skip to content

Semax

ACTH (4-10) analogueMet-Glu-His-Phe-Pro-Gly-Pro
Approved for another indication

Evidence

Approved (ex-US)

Half-life

0.5 h

Typical vial

5 mg

Route

Nasal

What it is

A seven-amino-acid peptide developed in Russia and approved there for stroke and cognitive indications. It holds no approval elsewhere and is used nasally rather than injected.

Reviewed 12 Aug 2026

Semax is a synthetic analogue of a fragment of ACTH, developed in Russia in the 1980s. It occupies an unusual regulatory position: it is an approved medicine in Russia, listed on their essential medicines list, and used clinically there for stroke and cognitive indications. It has no approval anywhere else.

That matters for how the evidence reads. A substantial clinical literature exists, and most of it is Russian-language, conducted domestically, and has not been replicated by independent groups elsewhere. That is not a reason to dismiss it, and it is not the same as the multi-centre international evidence behind an FDA-approved drug. Both statements are true and readers usually get only one.

It is also unusual here in route: semax is used as a nasal solution, not injected. Anything on this page about drawing and reconstituting concerns preparing drops, not a syringe.

How it works

Semax has been reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in the brain, signalling proteins involved in neuron survival and plasticity. That is the most-cited proposed mechanism for the cognitive claims.

It also appears to influence the melanocortin system, unsurprisingly given it derives from an ACTH fragment, though the fragment was chosen specifically to avoid the parent hormone's effects on cortisol.

Nasal administration is used because it is small enough to reach the brain by that route with less first-pass loss than swallowing it would involve.

What it is studied for

Each entry states the evidence behind it. We do not rank indications by effectiveness — for most compounds here, that would be a claim nobody can support.

  • Stroke recovery

    Published review

    Its approved indication in Russia.

    EvidenceRussian clinical studies. Not replicated by independent groups outside Russia, and not reviewed by any other regulator.

  • Cognition and focus

    Published review

    The reason it is used outside Russia.

    EvidenceRussian clinical and preclinical work. No independent controlled trial in healthy adults.

Regulatory status

Last reviewed 12 Aug 2026. Positions in this category change frequently, so we date the line.

United States

Approved and clinically used in Russia, where it appears on the essential medicines list. Not approved in the United States, the EU or the UK, and material sold in those markets is an unapproved substance with no manufacturing standard behind it.

Identity and clearance

What the molecule is, and how long a dose stays measurable.

Published review

Molecule

Class
ACTH (4-10) analogue, heptapeptide
Molecular weight
813.9 Da
Length
7 amino acids

Sequence

Met-Glu-His-Phe-Pro-Gly-Pro

The Pro-Gly-Pro tail is a stabilising addition that considerably extends its life compared with the natural fragment.

Pharmacokinetics

Published review
Half-life0.5 h
Substantially cleared4 h
100%50%25%0%half-life 1hdose1h2h3h4h
Modelled from the half-life above, assuming first-order elimination. Illustrative rather than measured — it shows the shape of clearance, not a prediction for any individual.

Short-acting. Which is why dosing is described several times a day. Effects on neurotrophic factor expression are reported to outlast the peptide itself.

Dose protocols reported in sources

Displayed for reference only. Every row says where it came from, and a trial protocol and a community convention are not the same kind of information. None of this is fed into the calculator, and none of it is a recommendation.

Mixed sources

A week-by-week progression is also reported for Semax. See it against a 5 mg vial, where the syringe units can be worked out.

Dose protocols reported in sources, with the source of each.
GoalDoseFrequencyRouteUnits, 5 mg vialSourceStart this protocol
Commonly described nasal dose300 mcg – 600 mcgOnce or twice daily, split between nostrilsNasalUsed as drops. Higher ranges are described for the stroke indication in Russian clinical use, under supervision.12–24 uCommunity practiceStart this

The doses above in syringe units, for the vial you have:

Start this copies a row into a protocol of your own, which you can then edit. Where a source gave a dose range or an ambiguous frequency, those fields arrive empty — we will not pick a number on your behalf.

CheckRows marked community practice describe what people commonly do, drawn from public discussion. They are not derived from any trial and are not evidence that a dose is safe or effective.

Safety

Reported effects, the situations that need care, and the ones that mean stop.

Read before dosing

Reported effects

  • Nasal irritation or drynessCommunity practice

    Commonly reported

    The most frequent complaint, and a direct consequence of the route.

  • HeadacheCommunity practice

    Occasionally reported

  • Overstimulation, irritability or disturbed sleepCommunity practice

    Occasionally reported

    More often described with evening dosing or higher amounts.

  • Long-term effects outside clinical supervisionCommunity practice

    Unknown

    Its clinical use in Russia is short-course and supervised. Extended self-directed use is not what the evidence covers.

When to stop

  • Persistent nasal pain, bleeding or crusting.
  • Any allergic response: rash, facial swelling or difficulty breathing. Seek urgent care.
  • Marked anxiety, agitation or insomnia that appears after starting.
  • Any new neurological symptom — headache pattern change, visual disturbance, weakness.

Interactions and situations that need care

  • Pregnancy and breastfeedingAvoid

    No reproductive or developmental safety data outside Russian clinical use.

  • Anxiety disordersUse caution

    Overstimulation and irritability are among the more commonly reported effects, which is a poor fit alongside an anxiety disorder.

  • Stimulant medicationUse caution

    Semax is frequently described as stimulating. Combining it with prescribed stimulants adds an unquantified variable to a medication someone is already titrating.

What to expect

What the sources describe over time, and how confident anyone can be about it.

  • Human clinical evidence exists, and it is essentially all Russian, domestic, and unreplicated by independent groups elsewhere. Weigh it accordingly rather than dismissing or over-reading it.
  • Its approved use is a short supervised course, for stroke and specific cognitive indications. Not indefinite self-directed use in healthy adults.
  • Effects reported by users are typically described as subtle and same-day rather than accumulating.
  • Nasal irritation is the most consistently reported downside and follows from the route.

Storage and combinations

How to keep it, and what it does and does not go with.

Storage and handling

Freeze-dried powder
Refrigerated at 2–8 °C, protected from light.
After mixing
Refrigerated at 2–8 °C. Nasal solutions are entered repeatedly, so bacteriostatic water rather than sterile water matters here.
Long-term, frozen
Unopened powder is stable at −20 °C or colder.

Printable one-pagerHow to reconstitute a vial, step by step

With other peptides

  • The amidated form is a modified Semax. Running both is taking the same compound twice, once in a form with Russian clinical use behind it and once in a form with none.

  • Adamaxcaution

    Sold as a Semax derivative, so running both risks taking the same thing twice. With no established structure for Adamax, even that cannot be said with confidence.

  • Selanksynergistic

    Commonly used together — Semax described as stimulating, Selank as calming. Both come from the same research programme, and no study has tested the combination.

Check this against a whole stack

Stacks with Semax in them

Documented combinations and plans people have published, with full schedules.

Published by people running it. Their plans, not ours — one person doing something is not evidence that it works.

Checking your vial

Research chemicals carry no manufacturing standard, so what the vial looks like is often the only quality signal available before you use it.

  • White cake, clear solution

    Standard for a short peptide.

  • Cloudy solution

    Particularly relevant for a nasal preparation entered repeatedly over weeks.

Vocabulary on this page

Sterile technique
The handling that keeps a vial and an injection free of contamination: clean hands, an alcohol-wiped stopper, a fresh needle every time.
Bacteriostatic water
Sterile water containing a small amount of benzyl alcohol, which stops bacteria multiplying and allows a vial to be used more than once.
Evidence level
The category of human evidence behind a compound, from preclinical through to approved. Stated on every profile here as a category, not an adjective.
Stack
Several separate compounds run at the same time, each in its own vial and on its own schedule.
Peptide
A short chain of amino acids: the same building blocks as a protein, in a chain short enough to behave differently.
Protocol
One compound, with a dose, a frequency and a length: the plan, as opposed to what was actually taken.

The whole glossary →

Questions

Reader questions
Is Semax approved anywhere?
Yes, in Russia, where it is used clinically and appears on the essential medicines list. It holds no approval in the United States, the EU or the UK.
Why is the research all Russian?
It was developed in Russia in the 1980s and its clinical development happened there. Most of the literature is Russian-language and has never been replicated by an independent group. That is a real limitation, and a different one from having no evidence at all.
Is it injected?
No. Semax is used as a nasal solution. It is reconstituted into a dropper or spray rather than drawn into a syringe.

References

Everything on this page that came from a source, with the source.

  1. Semax, an analogue of ACTH(4-7): neuroprotective and nootropic activity

    Review literature, 2018 · Review

    Humans and animal models

    Reviews reported increases in BDNF and NGF expression, and summarises Russian clinical use in stroke and cognitive indications.

  2. Commonly reported community protocols

    BioAlmanac editorial summary of public community sources, 2026 · Not a study

    Summarises nasal dose ranges described in public discussion outside Russia. Carries no evidential weight about safety or effect.

  3. Compiled community protocols

    BioAlmanac editorial summary of a public protocol compilation, 2026 · Not a study

    Records a week-by-week progression described on a vendor-adjacent protocol site, retrieved August 2026. Only the doses are taken from it. Its own syringe-unit conversions were checked against the vial sizes it states and several understate the volume by half, so nothing computed by that source is reproduced here — the units on this site are worked out from the vial in front of you. Carries no evidential weight about safety or effect.

Keep this page honest

If something here is wrong, out of date, or missing a source, tell us and we will fix it and say that we did.

Suggest a correction

This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on BioAlmanac is medical advice. No clinician reviews these pages.

Page last updated 12 Aug 2026